Medindia

X

Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P

by Medindia Content Team on  July 26, 2006 at 4:57 AM Drug News   - G J E 4
Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
Pharma company Lupin Ltd today said it has received approval from the Drugs Controller General (India) (DCGI) to conduct Phase II clinical trials for the molecule LL-42 18 (Desoside-P).
Advertisement

The company received permission to continue Phase II clinical trials on the Psoriasis pure compound, LL-42 18, after DCGI found the clinical Phase I data of the molecule to be satisfactory.

Advertisement
Lupin informed the Bombay Stock Exchange that it intends to begin clinical trials at 5-6 centres immediately.

'We are delighted that our Phase I data has been found to be satisfactory for us to proceed with further clinical trials. We are very excited with taking the molecule forward and look forward to meeting this otherwise unmet market need,' Company Chairman Desh Bandhu Gupta said.

LL-4218, a pure molecule, is obtained from a plant source and is intended for the treatment of chronic stable plaque type psoriasis. This molecule's novel mechanism of action leads to marked psoriatic lesion improvement without any toxic effects.

The company said it also has three other new chemical entities in various stages of clinical trials.

Source:PTI News
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All